AMAbdulaziz F. Al Mana

Abdulaziz F. Al Mana

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abdulaziz F. Al Mana has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Abby Keeler

    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, USA

    1 shared publication
  • Amer Beitinjaneh

    Department of Medicine, Transplantation and Cellular Therapy, University of Miami Miller School of Medicine, Miami, FL 33136, USA

    1 shared publication
  • Andrea P. Espejo Freire

    Department of Medicine The Masonic Cancer Center The University of Minnesota Medical School University of Minnesota Minneapolis Minnesota USA

    1 shared publication
  • Antonio M. Jimenez Jimenez

    Department of Medicine, Transplantation and Cellular Therapy, University of Miami Miller School of Medicine, Miami, FL 33136, USA

    1 shared publication
  • Bharat Thyagarajan

    Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis

    1 shared publication
  • Brad Brown

    ChromaCode, Inc., Carlsbad, USA

    1 shared publication

Latest Publications

  • Transfusion support after CAR-T cell therapy: Real-world patterns across commercial products and disease groups

    by Jay Patel, Denise L. Pereira, Damian Green, Amer Beitinjaneh, Noa G. Holtzman, Mark S. Goodman, Antonio M. Jimenez Jimenez, Lazaros Lekakis, Jay Spiegel, Trent Wang, et al.


  • Performance of a Rapid Digital PCR Test for the Detection of Non-Small Cell Lung Cancer (NSCLC) Variants

    by Abdulaziz F. Al Mana, Kristen Culp, Abby Keeler, Orlando Perrera, Malini Rajagopalan, Lucien Jacky, Brad Brown, Bharat Thyagarajan

    Background Next-generation sequencing is widely used for comprehensive molecular profiling for many cancers including lung cancer. However, the complex workflows and long turnaround times limit its access and utility. ChromaCode’s High Definition PCR Non-Small Cell Lung Cancer Panel (HDPCR™ NSCLC Panel) is a low-cost, rapid turnaround, digital polymerase chain reaction assay that is designed to detect variants in nine NSCLC genes listed in National Comprehensive Cancer Network guidelines. Methods This assay uses TaqMan® probe limiting chemistry and proprietary analysis software to enable multi-target detection within a single-color channel. We compared the performance of the HDPCR™ NSCLC Panel against an in-house, laboratory-developed, targeted next-generation sequencing panel used in the Molecular Diagnostics Laboratory at the University of Minnesota Medical Center to detect biomarkers for NSCLC. Results The overall accuracy of the HDPCR panel was 99.48% (95% confidence interval 99.01–99.76) with a sensitivity of 95.35% (95% confidence interval 88.52–98.72) and a specificity of 99.69% (95% confidence interval 99.29–99.90). The HDPCR wet lab workflow was 4 h, and the time to generate variant calls from raw data using the ChromaCode Cloud was 2 minutes. Conclusions We demonstrated that the HDPCR™ NSCLC Panel provides timely, comprehensive, and sensitive mutation detection in NSCLC samples with results in less than 24 h.


  • Review of Current Advances in Serologic Testing for COVID-19

    by Andrea P Espejo, Yamac Akgun, Abdulaziz F Al Mana, Youley Tjendra, Nicolas C Millan, Carmen Gomez-Fernandez, Carolyn Cray

    Objectives: To examine and summarize the current literature on serologic methods for the detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Methods: A literature review was performed using searches in databases including PubMed, medRxiv, and bioRxiv. Thirty-two peer-reviewed papers and 23 preprints were examined. Results: The studies included lateral flow immunoassay, enzyme-linked immunosorbent assay, chemiluminescence immunoassay, and neutralizing antibody assays. The use of all major SARS-CoV-2 antigens was demonstrated to have diagnostic value. Assays measuring total antibody reactivity had the highest sensitivity. In addition, all the methods provided opportunities to characterize the humoral immune response by isotype. The combined use of IgM and IgG detection resulted in a higher sensitivity than that observed when detecting either isotype alone. Although IgA was rarely studied, it was also demonstrated to be a sensitive marker of infection, and levels correlated with disease severity and neutralizing activity. Conclusions: The use of serologic testing, in conjunction with reverse transcription polymerase chain reaction testing, was demonstrated to significantly increase the sensitivity of detection of patients infected with SARS-CoV-2. There was conflicting evidence regarding whether antibody titers correlated with clinical severity. However, preliminary investigations indicated some immunoassays may be a surrogate for the prediction of neutralizing antibody titers and the selection of recovered patients for convalescent serum donation.